当前位置：
X-MOL 学术
›
Oncologist
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
The Oncologist ( IF 5.8 ) Pub Date : 2023-10-03 , DOI: 10.1093/oncolo/oyad257 Çağlar Ünal 1 , Abdulmunir Azizy 2 , Senem Karabulut 2 , Didem Taştekin 2 , Arif Akyıldız 3 , Serkan Yaşar 3 , Şuayib Yalçın 3 , Eyüp Çoban 4 , Türkkan Evrensel 4 , Ziya Kalkan 5 , Zeynep Oruç 5 , Sümeyra Derin 6 , Zeynep Hande Turna 6 , Doğan Bayram 7 , Fahriye Tuğba Köş 7 , Mehmet Ali Nihat Şendur 7 , Nadiye Sever 8 , Özlem Ercelep 8 , Mustafa Seyyar 9 , Umut Kefeli 9 , Kazım Uygun 9 , Melike Özçelik 10 , Sercan Ön 11 , Ulus Ali Şanlı 11 , Kübra Canaslan 12 , İlkay Tuba Ünek 12 , Kadriye Bir Yücel 13 , Nuriye Özdemir 13 , Ozan Yazıcı 13 , Halil Göksel Güzel 14 , Derya Kıvrak Salim 14 , Sema Sezgin Göksu 15 , Ali Murat Tatlı 15 , Çetin Ordu 16 , Oğuzhan Selvi 17 , Abdullah Sakin 18 , Mehmet Emin Büyükbayram 19 , Bengü Dursun 20 , Yüksel Ürün 20 , Hacı Arak 21 , Gözde Ağdaş 22 , Muzaffer Uğraklı 23 , Engin Hendem 23 , Melek Karakurt Eryılmaz 23 , Burak Bilgin 24 , Atakan Topçu 25 , Melih Şimşek 25 , Mahmut Büyükşimşek 26 , Büşra Akay 27 , Gülçin Şahingöz Erdal 28 , Fatih Karataş 29 , Özkan Alan 30 , Melek Çağlayan 31 , Fatma Akdağ Kahvecioğlu 32 , Ayşe Demirci 32 , Nail Paksoy 33 , Bülent Çetin 34 , Mahmut Gümüş 35 , Naziye Ak 36 , Yasemin Aydınalp 37 , Semra Paydaş 37 , Deniz Can Güven 38 , Saadettin Kılıçkap 39 , Sezer Sağlam 40
The Oncologist ( IF 5.8 ) Pub Date : 2023-10-03 , DOI: 10.1093/oncolo/oyad257 Çağlar Ünal 1 , Abdulmunir Azizy 2 , Senem Karabulut 2 , Didem Taştekin 2 , Arif Akyıldız 3 , Serkan Yaşar 3 , Şuayib Yalçın 3 , Eyüp Çoban 4 , Türkkan Evrensel 4 , Ziya Kalkan 5 , Zeynep Oruç 5 , Sümeyra Derin 6 , Zeynep Hande Turna 6 , Doğan Bayram 7 , Fahriye Tuğba Köş 7 , Mehmet Ali Nihat Şendur 7 , Nadiye Sever 8 , Özlem Ercelep 8 , Mustafa Seyyar 9 , Umut Kefeli 9 , Kazım Uygun 9 , Melike Özçelik 10 , Sercan Ön 11 , Ulus Ali Şanlı 11 , Kübra Canaslan 12 , İlkay Tuba Ünek 12 , Kadriye Bir Yücel 13 , Nuriye Özdemir 13 , Ozan Yazıcı 13 , Halil Göksel Güzel 14 , Derya Kıvrak Salim 14 , Sema Sezgin Göksu 15 , Ali Murat Tatlı 15 , Çetin Ordu 16 , Oğuzhan Selvi 17 , Abdullah Sakin 18 , Mehmet Emin Büyükbayram 19 , Bengü Dursun 20 , Yüksel Ürün 20 , Hacı Arak 21 , Gözde Ağdaş 22 , Muzaffer Uğraklı 23 , Engin Hendem 23 , Melek Karakurt Eryılmaz 23 , Burak Bilgin 24 , Atakan Topçu 25 , Melih Şimşek 25 , Mahmut Büyükşimşek 26 , Büşra Akay 27 , Gülçin Şahingöz Erdal 28 , Fatih Karataş 29 , Özkan Alan 30 , Melek Çağlayan 31 , Fatma Akdağ Kahvecioğlu 32 , Ayşe Demirci 32 , Nail Paksoy 33 , Bülent Çetin 34 , Mahmut Gümüş 35 , Naziye Ak 36 , Yasemin Aydınalp 37 , Semra Paydaş 37 , Deniz Can Güven 38 , Saadettin Kılıçkap 39 , Sezer Sağlam 40
Affiliation
INTRODUCTION
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).
METHODS
We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.
RESULTS
The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.
CONCLUSIONS AND RELEVANCE
The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
中文翻译：
卡培他滨和替莫唑胺方案对神经内分泌肿瘤的疗效：来自土耳其肿瘤学组的数据。
简介 本研究旨在报告卡培他滨联合替莫唑胺 (CAPTEM) 在不同治疗方案中对转移性神经内分泌肿瘤 (NET) 患者的疗效和安全性。方法 我们进行了一项多中心回顾性研究，分析了 2010 年至 2022 年土耳其不同地区 34 家不同医院的 308 名转移性 NET 患者接受 CAPTEM 治疗的数据。结果中位随访时间为41.0个月（范围：1.7-212.1），中位年龄为53岁（范围：22-79）。我们对整个患者队列的结果显示，中位无进展生存期 (PFS) 为 10.6 个月，中位总生存期 (OS) 为 60.4 个月。一线 CAPTEM 治疗似乎更有效，中位 PFS 为 16.1 个月，中位 OS 为 105.8 个月（一线、二线和≥三线的中位 PFS 分别为 16.1、7.9 和 9.6 个月，P = .01 ；中位 OS 值分别为 105.8、47.2 和 24.1 个月，P = .003）就 ORR 而言，一线治疗再次表现更好，ORR 为 54.7%，而一线治疗的 ORR 为 33.3% 和 30.0%分别为第二行和第三行或更高行 (P < .001)。仅 22.5% 的患者出现 3-4 级副作用，导致停药率为 9.5%。尽管不同治疗线的结果存在差异，但我们没有观察到第一线治疗和后续治疗线之间副作用方面存在显着差异。结论和相关性 接受一线 CAPTEM 治疗的患者的显着优异结果凸显了其作为转移性 NET 患者有效治疗策略的潜力。
更新日期：2023-10-03
中文翻译：
卡培他滨和替莫唑胺方案对神经内分泌肿瘤的疗效：来自土耳其肿瘤学组的数据。
简介 本研究旨在报告卡培他滨联合替莫唑胺 (CAPTEM) 在不同治疗方案中对转移性神经内分泌肿瘤 (NET) 患者的疗效和安全性。方法 我们进行了一项多中心回顾性研究，分析了 2010 年至 2022 年土耳其不同地区 34 家不同医院的 308 名转移性 NET 患者接受 CAPTEM 治疗的数据。结果中位随访时间为41.0个月（范围：1.7-212.1），中位年龄为53岁（范围：22-79）。我们对整个患者队列的结果显示，中位无进展生存期 (PFS) 为 10.6 个月，中位总生存期 (OS) 为 60.4 个月。一线 CAPTEM 治疗似乎更有效，中位 PFS 为 16.1 个月，中位 OS 为 105.8 个月（一线、二线和≥三线的中位 PFS 分别为 16.1、7.9 和 9.6 个月，P = .01 ；中位 OS 值分别为 105.8、47.2 和 24.1 个月，P = .003）就 ORR 而言，一线治疗再次表现更好，ORR 为 54.7%，而一线治疗的 ORR 为 33.3% 和 30.0%分别为第二行和第三行或更高行 (P < .001)。仅 22.5% 的患者出现 3-4 级副作用，导致停药率为 9.5%。尽管不同治疗线的结果存在差异，但我们没有观察到第一线治疗和后续治疗线之间副作用方面存在显着差异。结论和相关性 接受一线 CAPTEM 治疗的患者的显着优异结果凸显了其作为转移性 NET 患者有效治疗策略的潜力。
京公网安备 11010802027423号